Pharmacy Benefits Management – Page 59

May 27, 2021

Pylarify Approved for PET Imaging of Prostate Cancer

May 27, 2021 – The U.S. FDA has approved Pylarify^® (piflufolastat F 18), manufactured by Progenics Pharmaceuticals, for positron emission tomography (PET) of prostate-specific

May 27, 2021

Yervoy Receives Expanded Melanoma Indication for Adults

May 27, 2021 – The U.S. FDA has approved an expanded indication for Yervoy (ipilimumab), manufactured by Bristol Myers Squibb, to be used in combination with nivolumab to treat

May 27, 2021

Zeposia Becomes First-in-Class Treatment for Ulcerative Colitis

May 27, 2021 – The U.S. FDA has approved a new indication for Zeposia^® (ozanimod), manufactured by Bristol Myers Squibb, to treat adults who have moderately to severely

May 27, 2021

Nurtec ODT Granted Indication to Prevent Episodic Migraines

May 27, 2021 – The U.S. FDA has approved a new indication for Nurtec® ODT (rimegepant), manufactured by Biohaven, for the preventive treatment of episodic migraines

May 26, 2021

Investigational Drug Sotrovimab Granted Emergency Use Authorization for Outpatient Treatment of COVID-19

May 26, 2021 – The U.S. FDA has granted emergency use authorization (EUA) to GlaxoSmithKline’s

May 26, 2021

FDA Restricts Use of Ocaliva in Some Patients

May 26, 2021 – The U.S. FDA has issued a safety communication regarding the use of Ocaliva^® (obeticholic acid), manufactured by Intercept Pharmaceuticals, in certain patients who have

May 26, 2021

Myfembree Approved to Manage Heavy Menstrual Bleeding Due to Uterine Fibroids

May 26, 2021 – The U.S. FDA has approved Myfembree^® (relugolix 40mg/estradiol 1mg/norethindrone acetate 0.5mg), manufactured by Myovant and Pfizer

May 26, 2021

Camcevi Approved to Treat Prostate Cancer

May 26, 2021 – The U.S. FDA has approved Camcevi^® (leuprolide mesylate), manufactured by Foresee Pharmaceuticals, to treat advanced prostate cancer in adults.